Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
BRCA2 mutation
Cancer:
Solid Tumor
Drug:
ART558
(
POLQ inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Nat Commun
Title:
Pol? inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Published date:
06/17/2021
Excerpt:
In addition, ART558 elicits DNA damage and synthetic lethality in BRCA1- or BRCA2-mutant tumour cells...
DOI:
10.1038/s41467-021-23463-8
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login